JP7034950B2 - 抗ｈｌａ－ｇ特異的抗体 - Google Patents

抗ｈｌａ－ｇ特異的抗体 Download PDF

Info

Publication number
JP7034950B2
JP7034950B2 JP2018563104A JP2018563104A JP7034950B2 JP 7034950 B2 JP7034950 B2 JP 7034950B2 JP 2018563104 A JP2018563104 A JP 2018563104A JP 2018563104 A JP2018563104 A JP 2018563104A JP 7034950 B2 JP7034950 B2 JP 7034950B2
Authority
JP
Japan
Prior art keywords
antibody
hla
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528038A5 (enExample
JP2019528038A (ja
Inventor
ピエール・ラングラード・ドゥモイヤン
ティエリー・ユエ
ジュリアン・コーマルタン
マリア・ルストー
マリア・ヴェーブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invectys SAS
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of JP2019528038A publication Critical patent/JP2019528038A/ja
Publication of JP2019528038A5 publication Critical patent/JP2019528038A5/ja
Priority to JP2022031638A priority Critical patent/JP2022084670A/ja
Application granted granted Critical
Publication of JP7034950B2 publication Critical patent/JP7034950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
JP2018563104A 2016-06-03 2017-06-02 抗ｈｌａ－ｇ特異的抗体 Active JP7034950B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022031638A JP2022084670A (ja) 2016-06-03 2022-03-02 抗ｈｌａ－ｇ特異的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305650.0 2016-06-03
EP16305650 2016-06-03
PCT/EP2017/063503 WO2017207775A1 (en) 2016-06-03 2017-06-02 Anti hla-g specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022031638A Division JP2022084670A (ja) 2016-06-03 2022-03-02 抗ｈｌａ－ｇ特異的抗体

Publications (3)

Publication Number Publication Date
JP2019528038A JP2019528038A (ja) 2019-10-10
JP2019528038A5 JP2019528038A5 (enExample) 2020-06-18
JP7034950B2 true JP7034950B2 (ja) 2022-03-14

Family

ID=56413601

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563104A Active JP7034950B2 (ja) 2016-06-03 2017-06-02 抗ｈｌａ－ｇ特異的抗体
JP2022031638A Pending JP2022084670A (ja) 2016-06-03 2022-03-02 抗ｈｌａ－ｇ特異的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022031638A Pending JP2022084670A (ja) 2016-06-03 2022-03-02 抗ｈｌａ－ｇ特異的抗体

Country Status (15)

Country Link
US (5) US20190233520A1 (enExample)
EP (1) EP3464364A1 (enExample)
JP (2) JP7034950B2 (enExample)
KR (1) KR102465491B1 (enExample)
CN (2) CN109563169B (enExample)
AU (1) AU2017272875B2 (enExample)
BR (1) BR112018074847A2 (enExample)
CA (1) CA3025681A1 (enExample)
EA (1) EA201892793A1 (enExample)
IL (1) IL263266B2 (enExample)
MX (1) MX2018014979A (enExample)
NZ (2) NZ748929A (enExample)
SG (2) SG10202107205VA (enExample)
WO (1) WO2017207775A1 (enExample)
ZA (1) ZA201808332B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
NZ748929A (en) 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
AR114789A1 (es) * 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
SG11202013170RA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd Pd1-4-1bbl variant fusion protein and methods of use thereof
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
EP3827020A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
EP3843778A1 (en) * 2018-08-31 2021-07-07 Invectys Sa Chimeric antigen receptors against multiple hla-g isoforms
US11208487B2 (en) * 2018-09-27 2021-12-28 Tizona Therapeutics Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
AU2020331424A1 (en) * 2019-08-14 2022-03-31 Antlera Therapeutics Inc. Antibodies that bind to LRP6 proteins and methods of use
JP2022553073A (ja) * 2019-10-25 2022-12-21 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療・診断標的としてのｈｌａ－ｈ， ｈｌａ－ｊおよびｈｌａ－ｌ
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
EP4263609A1 (en) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anti-hla-g antibodies and use thereof
CN112794908A (zh) * 2020-12-31 2021-05-14 杭州冰湖生物科技有限公司 一种抗hla-g抗体的制备及分析方法
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CN115925930B (zh) * 2021-11-04 2025-10-31 台州恩泽医疗中心(集团) 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途
CN114605543B (zh) * 2021-12-17 2023-11-07 台州恩泽医疗中心(集团) 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途
WO2023150698A2 (en) 2022-02-04 2023-08-10 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
US20250297013A1 (en) * 2022-03-25 2025-09-25 Hk Inno.N Corporation Hla-g-specific antibody and use thereof
CN115819583B (zh) * 2022-03-31 2026-03-03 台州恩泽医疗中心(集团) 一种抗hla-g分子的单克隆抗体及其用途
CN115894687B (zh) * 2022-03-31 2024-06-07 台州恩泽医疗中心(集团) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途
CN116284387B (zh) * 2022-07-15 2025-10-03 台州恩泽医疗中心(集团) 一种抗hla-g2及hla-g6分子的单克隆抗体及用途
CN117448412A (zh) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d分子、其中和抗体，及应用
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
KR102793781B1 (ko) * 2023-10-12 2025-04-14 주식회사 아이엠바이오로직스 Hla-g에 특이적으로 결합하는 항체 및 이의 용도
CN121005780A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 靶向hla-g的抗体或其抗原结合片段及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072534A1 (en) 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CN1312182C (zh) * 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
EP2264067A1 (en) * 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
CN101967191A (zh) * 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
CN102086459A (zh) * 2009-12-08 2011-06-08 华中科技大学 一种融合蛋白免疫抑制剂及其制备方法和应用
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
AU2016243128A1 (en) 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
NZ748929A (en) 2016-06-03 2025-11-28 Invectys Anti hla-g specific antibodies
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072534A1 (en) 2012-11-12 2014-05-15 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Natl. Acad. Sci. USA，2003年，Vol. 100，p. 8856-8861

Also Published As

Publication number Publication date
SG10202107205VA (en) 2021-08-30
IL263266B1 (en) 2024-03-01
SG11201810149VA (en) 2018-12-28
MX2018014979A (es) 2019-10-14
IL263266A (en) 2018-12-31
KR20190044589A (ko) 2019-04-30
JP2022084670A (ja) 2022-06-07
US11312774B2 (en) 2022-04-26
EA201892793A1 (ru) 2019-06-28
KR102465491B1 (ko) 2022-11-11
US11111302B2 (en) 2021-09-07
US20210309748A1 (en) 2021-10-07
EP3464364A1 (en) 2019-04-10
US20190233520A1 (en) 2019-08-01
AU2017272875B2 (en) 2023-10-19
BR112018074847A2 (pt) 2019-03-26
US20220056140A1 (en) 2022-02-24
US11634494B2 (en) 2023-04-25
AU2017272875A1 (en) 2018-12-20
CA3025681A1 (en) 2017-12-07
ZA201808332B (en) 2019-08-28
NZ788807A (en) 2025-11-28
CN109563169B (zh) 2022-07-01
US20210054081A1 (en) 2021-02-25
NZ748929A (en) 2025-11-28
IL263266B2 (en) 2024-07-01
WO2017207775A1 (en) 2017-12-07
CN109563169A (zh) 2019-04-02
JP2019528038A (ja) 2019-10-10
US20220251216A1 (en) 2022-08-11
CN115286695A (zh) 2022-11-04

Similar Documents

Publication Publication Date Title
US11634494B2 (en) Anti HLA-G specific antibodies
US11919970B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
JP7215759B2 (ja) ４－１ｂｂ抗体およびその製造方法と使用
US10533055B2 (en) Antibodies and chimeric antigen receptors specific for CD19
JP6097690B2 (ja) 抗ｃｘｃｌ１３抗体およびそれを用いる方法
US20230365676A1 (en) Cd33 antibodies
RU2855103C1 (ru) Молекулы антитела к LILRB3 и их применение
EA043548B1 (ru) Анти-hla-g специфические антитела
WO2026063874A1 (en) B7-h3 antigen-binding molecules
WO2024179553A1 (zh) 靶向TGFβ的融合蛋白及其应用
CN118165107A (zh) 结合tigit的抗体分子
HK40042566A (en) Antibodies and chimeric antigen receptors specific for ror1
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
HK1246314B (en) Antibodies and chimeric antigen receptors specific for ror1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220302

R150 Certificate of patent or registration of utility model

Ref document number: 7034950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250